Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB fulfills the requirements for admission to trading of the company’s shares on the main market Nasdaq Stockholm. The first day
Nordic Life Science
NLS Pharma News
Pharma
TheUS Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart
Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding application to be listed on Nasdaq Stockholm’s main market, subject to customary conditions. The last day of trading on Nasdaq First
The company has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer
Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together
The company has announced the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to humans. The findings
Clinical trials
The company has presented detailed results from the Phase III CASPIAN trial, showing Imfinzi (durvalumab) significantly improved overall survival (OS)
The company has announced the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of
The company has announced positive results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of
The company has announced positive Phase II MERECA results, including complete tumor responses in metastatic renal cell carcinoma patients. The
The company has conducted site initiation visit at the Uppsala University Hospital in Uppsala and formally opened the first clinical
The company has announced new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04. The
The company has announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met theprimary
The company has announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multi-centre trial
The company announced that clinical responses were observed in 3 out of 9 patients in part 1 of the ONCOS-102
The company has completed a planned 12 week interim analysis in the its Phase 2 proof-of-concept study of its bispecific
The company announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) in
AstraZeneca and MSD have announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The
Targovax starts expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab
All safety reviews during the dose escalation phase have been completed with no Dose Limiting Toxicities (DLT) reported and the
The company has announced that all patients have completed treatment with SiPore15 in the STAR Trial Development is well on
The company has announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage
The company has announced that the first patient has been enrolled in the fimaChem RELEASE study with registration intent in
Profiles in Pharma
Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments